These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 21501627)

  • 1. Enhanced effects of amphetamine but reduced effects of the hallucinogen, 5-MeO-DMT, on locomotor activity in 5-HT(1A) receptor knockout mice: implications for schizophrenia.
    van den Buuse M; Ruimschotel E; Martin S; Risbrough VB; Halberstadt AL
    Neuropharmacology; 2011; 61(1-2):209-16. PubMed ID: 21501627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT(1A) and 5-HT(2A) receptors.
    Riga MS; Bortolozzi A; Campa L; Artigas F; Celada P
    Neuropharmacology; 2016 Feb; 101():370-8. PubMed ID: 26477571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice.
    Halberstadt AL; Koedood L; Powell SB; Geyer MA
    J Psychopharmacol; 2011 Nov; 25(11):1548-61. PubMed ID: 21148021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The serotonin hallucinogen 5-MeO-DMT alters cortico-thalamic activity in freely moving mice: Regionally-selective involvement of 5-HT
    Riga MS; Lladó-Pelfort L; Artigas F; Celada P
    Neuropharmacology; 2018 Nov; 142():219-230. PubMed ID: 29221792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats.
    Krebs-Thomson K; Ruiz EM; Masten V; Buell M; Geyer MA
    Psychopharmacology (Berl); 2006 Dec; 189(3):319-29. PubMed ID: 17013638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine.
    Halberstadt AL
    Pharmacol Biochem Behav; 2016 Apr; 143():1-10. PubMed ID: 26780349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clozapine does not require 5-HT1A receptors to block the locomotor hyperactivity induced by MK-801 Clz and MK-801 in KO1A mice.
    Scorza MC; Castañé A; Bortolozzi A; Artigas F
    Neuropharmacology; 2010; 59(1-2):112-20. PubMed ID: 20412811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors.
    Halberstadt AL; Buell MR; Masten VL; Risbrough VB; Geyer MA
    Psychopharmacology (Berl); 2008 Nov; 201(1):55-66. PubMed ID: 18604652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats.
    Fantegrossi WE; Harrington AW; Kiessel CL; Eckler JR; Rabin RA; Winter JC; Coop A; Rice KC; Woods JH
    Pharmacol Biochem Behav; 2006 Jan; 83(1):122-9. PubMed ID: 16460788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The absence of 5-HT(1A) receptors has minor effects on dopamine but not serotonin release evoked by MK-801 in mice prefrontal cortex.
    Castañé A; Artigas F; Bortolozzi A
    Psychopharmacology (Berl); 2008 Oct; 200(2):281-90. PubMed ID: 18594799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactive effects of mGlu5 and 5-HT2A receptors on locomotor activity in mice.
    Halberstadt AL; Lehmann-Masten VD; Geyer MA; Powell SB
    Psychopharmacology (Berl); 2011 May; 215(1):81-92. PubMed ID: 21153406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms.
    Jiang XL; Shen HW; Yu AM
    Pharmacol Rep; 2016 Jun; 68(3):608-15. PubMed ID: 26977821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The paradox of 5-methoxy-N,N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors.
    Winter JC; Filipink RA; Timineri D; Helsley SE; Rabin RA
    Pharmacol Biochem Behav; 2000 Jan; 65(1):75-82. PubMed ID: 10638639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs.
    Riga MS; Soria G; Tudela R; Artigas F; Celada P
    Int J Neuropsychopharmacol; 2014 Aug; 17(8):1269-82. PubMed ID: 24650558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychotropic drug-induced locomotor hyperactivity and prepulse inhibition regulation in male and female aromatase knockout (ArKO) mice: role of dopamine D1 and D2 receptors and dopamine transporters.
    Chavez C; Gogos A; Jones ME; van den Buuse M
    Psychopharmacology (Berl); 2009 Oct; 206(2):267-79. PubMed ID: 19597801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.
    Jiang XL; Shen HW; Yu AM
    Neuropharmacology; 2015 Feb; 89():342-51. PubMed ID: 25446678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abuse liability profile of three substituted tryptamines.
    Gatch MB; Forster MJ; Janowsky A; Eshleman AJ
    J Pharmacol Exp Ther; 2011 Jul; 338(1):280-9. PubMed ID: 21474568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines.
    Blair JB; Kurrasch-Orbaugh D; Marona-Lewicka D; Cumbay MG; Watts VJ; Barker EL; Nichols DE
    J Med Chem; 2000 Nov; 43(24):4701-10. PubMed ID: 11101361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discordant behavioral effects of psychotomimetic drugs in mice with altered NMDA receptor function.
    Benneyworth MA; Basu AC; Coyle JT
    Psychopharmacology (Berl); 2011 Jan; 213(1):143-53. PubMed ID: 20865248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.
    Depoortère R; Bardin L; Auclair AL; Kleven MS; Prinssen E; Colpaert F; Vacher B; Newman-Tancredi A
    Br J Pharmacol; 2007 May; 151(2):253-65. PubMed ID: 17375086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.